Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Jonasch on the Importance of Spotlighting Patient Advocacy in GU Malignancies

January 8th 2024

Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.

BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

January 4th 2024

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.

Future Outlooks in the Treatment of Advanced RCC

December 27th 2023

Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.

Data Updates in Advanced RCC from 2023 IKCS: North America

December 27th 2023

Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Combination Regimens Expand RCC and Prostate Cancer Treatment Armamentariums

December 26th 2023

Bupath highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and the potential uses for next-generation hormonal agents plus androgen deprivation therapy in frontline metastatic hormone-sensitive prostate cancer.

Dr Rini on the FDA Approval of Belzutifan in Advanced RCC

December 21st 2023

Brian I. Rini, MD, FASCO, discusses the significance of the FDA approval of belzutifan for the treatment of patients with advanced renal cell carcinoma

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

December 21st 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Approach to Collaborative Care in Bladder Cancer

December 21st 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Impact of Treatment Selection and Real-World Outcomes in Advanced RCC

December 20th 2023

Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.

Tackling Toxicity Management in Combination Regimens for Advanced RCC

December 20th 2023

A comprehensive discussion on toxicity management and patient tolerability for combination regimens in the setting of advanced RCC.

ctDNA Could Aid in Treatment Escalation and De-escalation Decisions in Kidney Cancer

December 19th 2023

Alan Tan, MD, discusses how utilizing circulating tumor DNA may provide valuable insight into when to escalate vs de-escalate treatment for patients with renal cell carcinoma.

Non–Clear Cell RCC Subtypes Require Individualized Approach to Treatment Selection

December 19th 2023

Jaime R. Merchán, MD, spotlights case studies of patients with rare non-ccRCC histologies, discussing their clinical presentation, recent data on immunotherapy and targeted treatment options for the management of these disease subtypes, and patient outcomes on these therapies.

Triple Combination Therapies in RCC: Clinical Trial Insights

December 19th 2023

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

RCC Research May Lead to SOC Improvements and Individualized Treatment Plans

December 15th 2023

Marijo Bilusic, MD, PhD, highlights key insights about renal cell carcinoma that were presented at the meeting covering considerations on sequencing TKIs, the need for further research to elucidate novel therapies, and the importance of offering clinical trials to all patients with genitourinary malignancies.

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

December 15th 2023

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

December 15th 2023

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

December 14th 2023

The FDA has approved belzutifan (Welireg) for the treatment of patients with advanced renal cell carcinoma (RCC) following a PD-1 or PD-L1 inhibitor and a VEGF TKI.

Frontline IO/TKI Regimens Continue to Evolve in ccRCC

December 14th 2023

Jaime R. Merchán, MD, discusses the evolution and current role of IO/TKI regimens in advanced RCC; highlights data from the phase 3 CLEAR and KEYNOTE-426 trials supporting the use of pembrolizumab-based regimens in untreated ccRCC; and speculates on how future biomarker-driven research could improve the benefit seen with these combinations in this disease.